@article{bfffc1a86a124f8b9463c4400f3272f4,
title = "ASO Author Reflections: Fibrinogen and Albumin Score Validated as a Prognostic Factor to Refine the Treatment Strategy for Esophageal Cancer Patients",
author = "Satoru Matsuda and Hiroya Takeuchi and Hirofumi Kawakubo and Ryo Takemura and Yusuke Maeda and Yuki Hirata and Takuji Kaburagi and Tomohisa Egawa and Tomohiko Nishi and Masaharu Ogura and Taku Miyasho and Akihiko Okamura and Shuhei Mayanagi and Kazumasa Fukuda and Rieko Nakamura and Tomoyuki Irino and Norihito Wada and Yuko Kitagawa",
note = "Funding Information: Yuko Kitagawa: Relevant financial activities outside the submitted work: Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd, Daiichi Sankyo Company, Ltd, Merck Serono Co., Ltd, Asahikasei Co., Ltd, EA Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd, Kaken Pharmaceutical Co., Ltd, Kowa Pharmaceutical Co., Ltd, Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd, Taisho Toyama Pharmaceutical Co., Ltd, Kyouwa Hakkou Kirin Co., Ltd, Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd, Nihon Pharmaceutical Co., Ltd, Japan Blood Products Organization Medtronic Japan Co., Ltd, Sanofi KK. Yuko Kitagawa received grants from Eisai Co., Ltd, Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd, and Fujifilm Toyama Chemical Co., Ltd. ",
year = "2020",
month = dec,
doi = "10.1245/s10434-020-09008-1",
language = "English",
volume = "27",
pages = "886--887",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
}
